Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and vascular function in chronic kidney disease
2021-002893-20Phase 3Active
- Sponsor
- Rouen University Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and cardiac morbidity comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change in brachial artery flow-mediated dilatation after reactive hyperemia. Started Oct 2021; status: active.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)cardiac morbidity
Beyond the preview
Go deeper on 2021-002893-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002893-20.